|
|
A Short Course on Regulatory Affairs with emphasis on the
Background, Content and Detail of Module 3 of the Common Technical Document (CTD), the ‘Quality Module’ |
TIMETABLE (tentative)
| 27 July 2011 |
Registration |
09.30h |
|
|
Day 1 Start |
10.00h |
Finish |
18.00h |
| |
Dinner |
19.15h |
|
| 28 July 2011 |
Day 2 Start |
08.45h |
Finish |
16.30h |
| |
| INTRODUCTION AND WELCOME |
INTRODUCTION TO THE INTERNATIONAL CONFERENCE ON HARMONISATION (ICH)
- ICH, its guidelines and the Common Technical Document (CTD)
- CTD Module 2.3 and Module 3
|
INTRODUCTION TO THE EUROPEAN REGULATORY SYSTEM:
- EU and Council of Europe operations and regulatory tasks
- Pharmaceutical legislation
- EU guidelines
- The European Pharmacopoeia
|
| INTRODUCTION TO THE ACTIVITIES AND INFLUENCE OF THE EUROPEAN PHARMACOPOEIA |
| THE PURPOSE, FORMAT AND CONTENT OF THE QUALITY OVERALL SUMMARY, CTD MODULE 2.3 |
STARTING TO BUILD CTD MODULE 3
- Understanding how the legislation, official guidelines, European Pharmacopoeia and other Council of Europe publications shape the required content of CTD Module 3
|
UNDERSTANDING DRUG SUBSTANCE ISSUES AND CONTRIBUTIONS TO CTD MODULE 3
-
Sourcing of drug substances, GMP, vendor verification, pedigree, QP certification
-
Starting and other materials in a chemical synthesis
- Chemistry development issues: characterisation, analytical validation, specifications and their justification
- Data provision options for manufacturing and control including Master Files and Certificates of Suitability
- ‘Conventional’ organic impurities
- Other impurities: residual solvents, residues of metal catalysts and reagents, inorganic impurities, genotoxic impurities, enantiomeric impurities
- Stability
- Specifications
|
UNDERSTANDING DRUG PRODUCT (DOSAGE FORM) ISSUES AND CONTRIBUTIONS TO CTD MODULE 3
- Starting and other materials in drug formulation
- Pharmaceutical development: composition, functions, optimisation, performance, bioequivalence
- Manufacturing process
- In-process and end-product control including specifications and their justification
- Stability
- Numerous examples
- Common deficiencies
|
Group Interactive Mini-Workshop #1
THE DRUG SUBSTANCE |
Group Interactive Mini-Workshop #2
PHARMACEUTICAL DEVELOPMENT |
|
EXCEPTIONAL VALUE: £995.00 + VAT
High-quality, carefully-structured training, accommodation for one night*, one breakfast, two lunches and a conference dinner, daytime in-course refreshments, a substantial delegates manual to reinforce the learning experience and a certificate of attendance
[14h Continuing Professional Development (CPD)]
* extra night(s) bookable if required, subject to availability |
| MORE ABOUT THE BACKGROUND TO THIS COURSE
AND
WHO SHOULD ATTEND
This Course will be a comprehensive and group interactive course that builds from first principles and explores numerous pharmaceutical topics that have to be addressed in supporting documentation for Marketing Authorisation Applications (MAAs).
The course has been well developed over many years and has been highly regarded by delegates of varied experience in regulatory affairs and associated departments. Past delegates have been and future ones are expected to be from within the pharmaceutical and chemical industries (chemical development, analytical, formulation and pharmaceutical development, manufacturing, regulatory/registration departments) and the Competent Authorities (assessors, inspectors, scientific/medical writers).
The course is suitable for people new or relatively new to regulatory affairs, particularly people transferring within a company into product registration work, and for those needing a refresher course or an up-to-date understanding of CTD Module3.
Book here
Please sign up for future announcements
|
|
|